Modern antiretroviral regimens
The article presents the results of major international studies (STARTMRK, ACTG A5257, SPRING 2, the SINGLE and FLAMINGO), which convincingly demonstrated the effectiveness and safety of drugs from the group of integrase inhibitors (raltegravir and dolutegravir) as part of ART regimens in HIV-infect...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2016-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1588 |
| Summary: | The article presents the results of major international studies (STARTMRK, ACTG A5257, SPRING 2, the SINGLE and FLAMINGO), which convincingly demonstrated the effectiveness and safety of drugs from the group of integrase inhibitors (raltegravir and dolutegravir) as part of ART regimens in HIV-infected patients who are just beginning treatment (first line regimens). Comparisons within 2–5 years regimens that included II or EFV, showed comparable or greater virological and immunological efficacy of RAL and DTG at a substantially lower incidence of adverse events with the use of these drugs. Preparations of the RAL group and DTG are the drugs of choice and special categories of patients with HIV infection (patients with tuberculosis or chronic hepatitis C). The article presents the results of two studies carried out in Russia, on the efficacy and safety of raltegravir in ART regimens in patients with HIV infection and tuberculosis, and in patients with HIV infection and chronic hepatitis C. |
|---|---|
| ISSN: | 2079-701X 2658-5790 |